Patent EP0293181A1 successfully refreshed from Google Patents.
EP0293181A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Cis-acting repression sequences, cis-acting anti-repression sequences, vectors, methods of preparation and use
Assignee: Dana Farber Cancer Institute Inc
•
Filing: 1988-05-25
•
Granted: —
•
Expires: 2008-05-25
Abstract
Abstract Cis -acting repression sequences which are able to provide a cis -acting inhibitory effect on the expression of a gene when placed downstream of the gene in its untranslated message are dislcosed. Cis -acting anti-repression sequences which can relieve the cis -acting repression in the presence of the art gene product are also disclosed. These sequences correspond to a sufficient number of nucleotides from the HIV-I, HIV-2, STLV-3 or HTLV-IV genomes to provide the repression or anti-repression effects. The use of the sequences in vectors and systems to control the expression of a desired gene product is also described.
Inventors
- 👤 William A. Haseltine
- 👤 Craig A. Rosen
- 👤 Joseph Gerald Sodroski
- 👤 Ernest Terwilliger
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 14:46
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/61; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/63; C12N15/79; C12N15/85
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
51 words
A cis -acting regulatory sequence comprising a sufficient number of nucleotides corresponding to nucleotides in the 3′portion of the genome of the group consisting of HIV-I, HIV-2, HTLV-IV and STLV-3 to provide a cis -acting repression effect on a gene when inserted downstream of the gene in the gene's untranslated message.
Claim 2
Dependent Claim
51 words
A cis -acting regulatory sequence comprising a sufficient number of nucleotides corresponding to nucleotides in the 3′portion of the genome of the group consisting of HIV-I, HIV-2, HTLV-IV and STLV-3 to provide a cis -acting repression effect on a gene when inserted downstream of the gene in the gene's untranslated message.
Claim 3
Dependent Claim
24 words
The cis -acting regulatory sequence of claim 1, wherein it corresponds to a sufficient number of nucleotides from region 6376-6725 of the HIV-I genome.
Claim 4
Dependent Claim
24 words
The cis -acting regulatory sequence of claim 1, wherein it corresponds to a sufficient number of nucleotides from region 7283-7325 of the HIV-I genome.
Claim 5
Dependent Claim
24 words
The cis -acting regulatory sequence of claim 1, wherein it corresponds to a sufficient number of nucleotides from region 5893-6538 of the HIV-I genome.
Claim 6
Dependent Claim
24 words
The cis -acting regulatory sequence of claim 1, wherein it corresponds to a sufficient number of nucleotides from region 8204-8497 of the HIV-I genome.
Claim 7
Dependent Claim
46 words
A cis -acting anti-repression sequence which comprises a sufficient number of nucleotides of the genome of the group consisting of HIV-I, HIV-2, HTLV-IV and STLV-3 to counteract a cis -acting repression effect on a gene in the presence of an effective amount of art gene product.
Claim 8
Dependent Claim
46 words
A cis -acting anti-repression sequence which comprises a sufficient number of nucleotides of the genome of the group consisting of HIV-I, HIV-2, HTLV-IV and STLV-3 to counteract a cis -acting repression effect on a gene in the presence of an effective amount of art gene product.
Claim 9
Dependent Claim
24 words
The cis -acting anti-repression sequence of claim 6, wherein it corresponds to a sufficient number of nucleotides from region 6969-7163 of the HIV-I genome.
Claim 10
Dependent Claim
24 words
The cis -acting anti-repression sequence of claim 6, wherein it corresponds to a sufficient number of nucleotides from region 7283-7325 of the HIV-I genome.
Claim 11
Dependent Claim
110 words
A vector containing (a) a desired gene and downstream in its untranslated message: (b) a cis -acting repression sequence (CRS), where the CRS contains a sufficient number of nucleotides corresponding to the 3′ portion of a genome of the group consisting of HIV-I, HIV-2, HTLV-IV and STLV-3 to provide a cis -acting repression effect on the desired gene, and (c) a cis -acting anti-repression (CAR) sequence containing a sufficient number of nucleotides corresponding to the 3′-region of the genome of the group consisting of HIV-I, HIV-2, HTLV-IV and STLV-3 to counteract the cis -acting repression effect of the CRS in the presence of a sufficient amount of art gene product.
Claim 12
Dependent Claim
110 words
A vector containing (a) a desired gene and downstream in its untranslated message: (b) a cis -acting repression sequence (CRS), where the CRS contains a sufficient number of nucleotides corresponding to the 3′ portion of a genome of the group consisting of HIV-I, HIV-2, HTLV-IV and STLV-3 to provide a cis -acting repression effect on the desired gene, and (c) a cis -acting anti-repression (CAR) sequence containing a sufficient number of nucleotides corresponding to the 3′-region of the genome of the group consisting of HIV-I, HIV-2, HTLV-IV and STLV-3 to counteract the cis -acting repression effect of the CRS in the presence of a sufficient amount of art gene product.
Claim 13
Dependent Claim
16 words
The vector of claim 9, wherein the CRS and CAR sequence corresponds to the HIV-I genome.
Claim 14
Dependent Claim
17 words
The vector of claim 9, wherein the CRS and the CAR sequence corresponds to the HIV-2 genome.
Claim 15
Dependent Claim
17 words
The vector of claim 9, wherein the CRS and the CAR sequence corresponds to the HTLV-IV genome.
Claim 16
Dependent Claim
17 words
The vector of claim 9, wherein the CRS and the CAR sequence corresponds to the STLV-3 genome.
Claim 17
Dependent Claim
26 words
The vector of claim 10, which also contains an HIV-I LTR 3′ to the desired gene and an HIV-I LTR 5′to the CRS and CAR sequence.
Claim 18
Dependent Claim
27 words
The vector of claim 11, which also contains an HIV-2 LTR 3′ to the desired gene and an HIV-2 LTR 5′ to the CRS and CAR sequence.
Claim 19
Dependent Claim
27 words
The vector of claim 11, which also contains an HTLV-IV LTR 3′ to the desired gene and an HTLV-IV LTR 5′ to the CRS and CAR sequence.
Claim 20
Dependent Claim
27 words
The vector of claim 11, which also contains an STLV-3 LTR 3′ to the desired gene and an STLV-3 LTR 5′ to the CRS and CAR sequence.
Claim 21
Dependent Claim
13 words
The vector of claim 9, wherein the desired gene is a heterologous gene.
Claim 22
Dependent Claim
60 words
A method for controlling the production of a desired gene product which comprises: (a) transfecting a preselected cell line with the vector of claim 9; and (b) at a predetermined time, contacting the CAR sequence with a sufficient amount of art gene product to activate the CAR sequence to repress the CRS and permit expression of the desired gene product.
Claim 23
Dependent Claim
42 words
The method of claim 19, wherein the preselected cell line is a tat cell line containing a tat gene corresponding to a viral genome and the vector also contains an LTR segment derived from the viral genome corresponding to the tat gene.
Claim 24
Dependent Claim
26 words
The method of claim 20, wherein the art gene product is contacted with the transfected cell by use of a vector containing an operable art gene.
Claim 25
Dependent Claim
38 words
The method of claim 19, wherein the art gene product is under the control of a secondary factor which is activated at the predetermined time to express sufficient amounts of the art gene product to activate the CAR.
Claim 26
Dependent Claim
56 words
A vector containing a desired gene upstream of a segment containing a sufficient number of nucleotides corresponding to region 6376-7760 of the HIV-I genome to provide a cis -acting repression effect on the desired gene in the absence of art gene product wherein this cis -acting effect is counteracted in the presence of art gene product.
Claim 27
Dependent Claim
56 words
A vector containing a desired gene upstream of a segment containing a sufficient number of nucleotides corresponding to region 6376-7760 of the HIV-I genome to provide a cis -acting repression effect on the desired gene in the absence of art gene product wherein this cis -acting effect is counteracted in the presence of art gene product.
Claim 28
Dependent Claim
60 words
A method for controlling the production of a desired gene product which comprises: (a) transfecting a preselected cell line with the vector of claim 23; and (b) at a predetermined time, contacting the CAR sequence with a sufficient amount of art gene product to activate the CAR sequence to repress the CRS and permit expression of the desired gene product.
Claim 29
Dependent Claim
17 words
The method of claim 24 wherein the vector contains an HIV-I LTR 3′ to the desired gene.
Claim 30
Dependent Claim
16 words
The method of claim 25 wherein the preselected cell line is a tat III cell line.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.